USP to revise Part D drug guidelines
Executive Summary
U.S. Pharmacopeia's Model Guidelines Expert Committee will meet Nov. 1-2 to discuss revisions to the list of drug categories and classes to be used by Medicare Part D drug plans in developing formularies. The group will update the guidelines to account "for new Part D drugs and new therapeutic uses of Part D drugs." USP will submit draft revised guidelines and a final report to the Centers for Medicare & Medicaid Services by Jan. 30. The initial guidelines, issued in December 2004, were followed by about half of the prescription drug plans that submitted formularies to CMS (1"The Pink Sheet" Sept. 26, 2005, p. 17)...
You may also be interested in...
USP Formulary Guidelines Adopted By Half Of Medicare Drug Plans
About half of Medicare prescription drug plans submitted to CMS followed the formulary guidelines created by the U.S. Pharmacopeia
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.